CN1899578A - Medicine for auxiliary treating hepatitis - Google Patents

Medicine for auxiliary treating hepatitis Download PDF

Info

Publication number
CN1899578A
CN1899578A CN 200610090972 CN200610090972A CN1899578A CN 1899578 A CN1899578 A CN 1899578A CN 200610090972 CN200610090972 CN 200610090972 CN 200610090972 A CN200610090972 A CN 200610090972A CN 1899578 A CN1899578 A CN 1899578A
Authority
CN
China
Prior art keywords
radix
hepatitis
chinese medicine
tiopronin
medicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN 200610090972
Other languages
Chinese (zh)
Other versions
CN100353992C (en
Inventor
李京红
王俊芳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CNB200610090972XA priority Critical patent/CN100353992C/en
Publication of CN1899578A publication Critical patent/CN1899578A/en
Application granted granted Critical
Publication of CN100353992C publication Critical patent/CN100353992C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention discloses synergistic medicinal composition of tiopronin and Chinese medicine extract and the application of the composition in preparing medicine for auxiliary treatment of hepatitis.

Description

The medicine of adjuvant treating hepatitis
Invention field
The present invention relates to the Pharmaceutical composition formed by tiopronin and Chinese medicine extract, and the purposes of said composition in the medicine of preparation adjuvant treating hepatitis.
Background technology
Hepatitis has multiple sorting technique clinically, classifies as (1) nosetiology: viral hepatitis can be divided into five types is first, second, third, fourth, penta.(2) clinical classification can be divided into following a few type: 1. acute anicteric hepatitis, this is a modal type in the viral hepatitis, see with B-mode, third type, hepatitis D more, general this type of hepatitis clinical symptoms is less, and transaminase's elevated levels is lower, and Histological change is light, mortality rate is lower, but the course of disease can be delayed the long period, and " three is slow " characteristics are arranged, and morbidity is slow, recovery is slow, delay also slow (referring to the long meaning slowly); 2. acute icterohepatitis is less relatively compared with anicteric hepatitis, and the state of an illness is a self limiting often, and how good prognosis is, but minority can develop into hepatitis gravis; 3. chronic hepatitis: relevant experts in 1994 propose the name and the suggestion of chronic hepatitis again, with the cause of disease is the diagnosis name that chronic hepatitis is determined on the basis, simultaneously ordered grade scale, formulated standard by stages according to degree of hepatic fibrosis again according to the downright bad order of severity of hepatitis inflammation; 4. hepatitis gravis can be divided into acute heavy type, severe subacute and chronic heavy type again; 5. cholestatic hepatitis.
Wherein hepatitis B is caused by hepatitis B virus, serves as main a kind of infectious disease that also can cause multiple organ injury with the liver inflammatory lesion.China is the most popular country of hepatitis B, reaches more than 35% some local crowd infection rate, and be the most serious infectious disease of current harm people ' s health.According to investigations, China's hepatitis B patient is about 2,700 ten thousand, and annual New Development patient about 9,000,000.
The hepatitis B clinical manifestation is various, easily develops into chronic hepatitis and liver cirrhosis, and a few peoples finally develop into hepatocarcinoma.Hepatic fibrosis is the total pathological change of many chronic hepatopathy evolutions, and the damage of chronic, persistence is the prerequisite that hepatic fibrosis forms.Cause the factor of hepatic injury a lot,, hepatitis B, liver cirrhosis, take some drugs for a long time and can cause acute and chronic liver injury generally because of factors such as medicine, a large amount of ethanol, allergy cause acute liver damage.By reducing detrimental effect to liver function, can adjuvant treating hepatitis.
The medicine that is used for the treatment of the acute and chronic hepatic injury at present, commonly used have tiopronin, a diammonium glycyrrhizinate etc.These chemicalses generally have certain side effect, and cause that therapeutic effect at a specified future date is poor, problem such as Strain produces after drug resistance phenomenon, the drug withdrawal relapse rate height.
The curative effect of Chinese medicine hepatitis B is proved by a large amount of clinical trials.Chinese medicine all can be brought into play curative effect preferably at aspects such as antiviral, adjusting immunity of organisms, protection hepatocyte.But Chinese medicine preparation ubiquity onset at present is slow, needs problems such as life-time service.
Therefore, Western medicine and Chinese Medicine and Clavicular need be got up, i.e. synergism is played in Chinese medicine and western medicine combination, solves the problem that above-mentioned Western medicine and Chinese medicine exist in auxiliary treatment all kinds hepatitis separately, produces synergistic therapeutic effect simultaneously.
Summary of the invention
One object of the present invention is to provide the Pharmaceutical composition of being made up of tiopronin and a kind of Chinese medicine extract, and wherein the Chinese medicine extract of said composition prepares according to the method for embodiment 1 among the Chinese patent CN1067267C, and is as follows:
With Radix Salviae Miltiorrhizae 12g, Poria 10g, Carapax Trionycis 16g, Radix Astragali 15g, Herba Artemisiae Scopariae 15g, Radix Isatidis 14g, Radix Angelicae Sinensis 12g, Radix Codonopsis 12g, Fructus Schisandrae Chinensis 15g, Rhizoma Polygoni Cuspidati 10g, Pericarpium Citri Reticulatae 10g, Ganoderma 12g, Radix Bupleuri 14g, Radix Glycyrrhizae 10g, Radix Curcumae 12g, Herba Patriniae 14g; Above-mentioned raw materials is decocted with water 3 times, merge each filtrate, concentrate, drying gets extractum.
One object of the present invention is to provide the purposes of above-mentioned Pharmaceutical composition in preparation auxiliary treatment all kinds hepatitis medicament.
This Chinese medicine the water extracted immersing paste is called " the described Chinese medicine extract of this paper (or above) " hereinafter.
Above-mentioned composition and mixing acceptable accessories can be made acceptable forms clinically, as tablet, capsule, granule, oral liquid, subcutaneous administration preparation, suppository etc.
Pharmacological research
The main pharmacodynamics of Pharmaceutical composition of the present invention studies confirm that it has strong transaminase lowering effect, i.e. function for protecting liver and reducing enzyme activity.
Edit with reference to Zhang Juntian, " modern pharmacology test method " (volume two), combined publication society of China Concord Medical Science University of Beijing Medical University, the 1397-1398 page or leaf, disclosed method in " first segment chmice acute chemical liver injury model ", set up the acute chemical liver injury model of mouse carbon tetrachloride, carry out the pharmacodynamics test of Pharmaceutical composition anti-liver injury of the present invention.
The test grouping:
1 normal control group: animal does not do any processing, and normal physiological saline is irritated stomach;
2 model control group: after the animal model modeling success, normal physiological saline is irritated stomach;
2 pure Chinese drug-treated group: the water extracted immersing paste 0.99g/kg body weight as indicated above
3 tiopronin groups: the 10mg/kg body weight is irritated stomach
4 compositions groups: 10mg/kg body weight tiopronin+the water extracted immersing paste 0.99g/kg body weight mentioned above is irritated stomach.
Following table has shown the influence of each group to Mouse Liver function leading indicator GOT, GPT.
Group Number of animals GOT (active unit) GPT (active unit)
The normal control group 10 20.78±16.75 48.31±17.35
Model control group 10 250.76±76.58 306.25±59.47
Pure Chinese drug-treated group 10 174.12±58.22 230.23±53.32
The tiopronin group 10 109.88±40.08 202.33±31.88
The compositions group 10 74.22±19.85 99.65±39.88
This table shows that all there is significant difference (P<0.05) in each group (pure Chinese drug-treated group, tiopronin group, compositions group) of treatment with model control group, and all there are significant difference (P<0.05) in compositions group and pure Chinese drug-treated group, compositions group and tiopronin group.Show that there are cooperative effect in tiopronin and described Chinese medicinal components in the compositions group.
The pharmaceutics test
Can produce the tablet that contains following component in a conventional manner:
Component Mg/ sheet
Pharmaceutical composition 200-1000 of the present invention
Corn starch 125.0
Pulvis Talci 75.0
Magnesium stearate 1.0
Wherein compositions is made up of with weight ratio tiopronin and Chinese medicine extract mentioned above at 1: 99.
Can produce the capsule that contains following component in a conventional manner:
Component Mg/ sheet
Pharmaceutical composition 200-1000 of the present invention
Lactose 10.0
Corn starch 20.0
Talcum 5.0
Wherein compositions is made up of with weight ratio tiopronin and Chinese medicine extract mentioned above at 1: 99.

Claims (2)

1 one kinds of Pharmaceutical compositions, it is made up of with weight ratio tiopronin and Chinese medicine extract at 1: 99, and described Chinese medicine extract prepares by following method:
With Radix Salviae Miltiorrhizae 12g, Poria 10g, Carapax Trionycis 16g, Radix Astragali 15g, Herba Artemisiae Scopariae 15g, Radix Isatidis 14g, Radix Angelicae Sinensis 12g, Radix Codonopsis 12g, Fructus Schisandrae Chinensis 15g, Rhizoma Polygoni Cuspidati 10g, Pericarpium Citri Reticulatae 10g, Ganoderma 12g, Radix Bupleuri 14g, Radix Glycyrrhizae 10g, Radix Curcumae 12g, Herba Patriniae 14g; Above-mentioned raw materials is decocted with water 3 times, merge each filtrate, concentrate, drying gets extractum.
2 compositionss as claimed in claim 1 using in the medicine of preparation adjuvant treating hepatitis.
CNB200610090972XA 2006-07-06 2006-07-06 Medicine for auxiliary treating hepatitis Expired - Fee Related CN100353992C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB200610090972XA CN100353992C (en) 2006-07-06 2006-07-06 Medicine for auxiliary treating hepatitis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB200610090972XA CN100353992C (en) 2006-07-06 2006-07-06 Medicine for auxiliary treating hepatitis

Publications (2)

Publication Number Publication Date
CN1899578A true CN1899578A (en) 2007-01-24
CN100353992C CN100353992C (en) 2007-12-12

Family

ID=37655690

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB200610090972XA Expired - Fee Related CN100353992C (en) 2006-07-06 2006-07-06 Medicine for auxiliary treating hepatitis

Country Status (1)

Country Link
CN (1) CN100353992C (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101474254B (en) * 2009-01-20 2011-06-08 中国人民解放军第四军医大学 Chinese medicinal composition for treating chronic hepatitis B and preparation method thereof
CN106619886A (en) * 2016-12-07 2017-05-10 郑州郑先医药科技有限公司 Chinese and western medicine composition containing japanese buttercup herb extract for treating hepatitis and preparation method thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1067267C (en) * 1998-04-24 2001-06-20 汪东平 Medicine for treating hepatitis B

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101474254B (en) * 2009-01-20 2011-06-08 中国人民解放军第四军医大学 Chinese medicinal composition for treating chronic hepatitis B and preparation method thereof
CN106619886A (en) * 2016-12-07 2017-05-10 郑州郑先医药科技有限公司 Chinese and western medicine composition containing japanese buttercup herb extract for treating hepatitis and preparation method thereof

Also Published As

Publication number Publication date
CN100353992C (en) 2007-12-12

Similar Documents

Publication Publication Date Title
CN100345585C (en) Drug comprising biphenyldicarboxylate
CN101810694B (en) Traditional Chinese medicine and western medicine composition for adjunctive therapy of hepatitis
CN100340268C (en) Synergistic medicinal composition containing tiopronin and Chinese medicine extract
CN100353992C (en) Medicine for auxiliary treating hepatitis
CN100356960C (en) Synergistic medicinal composition for treating hepatitis
CN100345584C (en) Synergistic medicinal composition containing diammonium glycyrrhizinate and Chinese medicine
CN100341534C (en) Synergistic medicinal composition
CN100421690C (en) Chinese-western medicine composition for treating hepatitis
CN100353981C (en) Medicine for auxiliary treating hepatitis
CN1899449A (en) Synergistic medicinal composition containing dicyclic alcohol
CN100345565C (en) Synergistic medicinal composition containing tiopronin and Chinese medicine extract
CN100345586C (en) Chinese traditional medicine and western medicine composition for treating hepatitis
CN1907416A (en) Medicinal compositions comprising biphenyldicarboxylate
CN1907399A (en) Cooperative medicinal composition comprising biphenyldicarboxylate and traditional Chinese medicine extract
CN1899492A (en) Synergistic medicinal composition for treating hepatitis
CN1907430A (en) Traditional Chinese medicine and western medicine compositions comprising biphenyldicarboxylate for treating hepatitis accessorily
CN101850003B (en) Traditional Chinese medicine and western medicine compound for protecting liver and decreasing enzyme
CN1907464A (en) Compositions comprising biphenyldicarboxylate
CN101797337B (en) Medicine containing Guadisu
CN1907431A (en) Traditional Chinese medicine and western medicine compositions comprising biphenyldicarboxylate
CN1899450A (en) Synergistic medicinal composition containing diammonium glycyrrhizinate and Chinese medicine
CN1907385A (en) Drug comprising biphenyldicarboxylate
CN1899433A (en) Synergistic medicinal composition
CN1899522A (en) Synergistic medicinal composition for treating hepatitis
CN1907354A (en) Drug for treating hepatitis comprising biphenyldicarboxylate

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee